New, innovative drugs are assessed within the so-called AMNOG process in Germany. Given the legal nature of this process, lawyers also play an important role. At the end of the AMNOG process there is a legal contract – and also important, lawyers are experienced in negotiations by nature? If this is true and how lawyers can support market access teams is discussed between the AMNOG expert Dr. Stefan Walzer and the experienced market access lawyer Alexander Meier.

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

 MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #AMNOG #law #lawyer

In this special podcast episode Dr. Stefan Walzer jumps into the latest trends and researches around market access, reimbursement and pricing presented and discussed just beginning of November 2022 at ISPOR Europe. From 6th to 9th of November the leading European experts including Dr. Stefan Walzer have met and discussed in Vienna. Discussion topics ranged widely around market access and pricing including buckets being discussed within this episode:

1) ATMPs

2) EU joint  HTA

3) Digital Health

4) Germany / AMNOG

5) European reimbursement

Please enjoy this compressed summary and let us know your questions that we should cover in the following podcast episodes. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany #europe #ispor #isporeurope

Given the current reforms and adaptions in the German system, one can wonder if the German market might remain the most attractive to launch pharmaceutical products and especially orphan drugs. Are there still ways to get innovative products into the market and get paid well? What do we need to know in order to still gain from the strengths of the German market size and economic power? This might be an even more important question in a global climate of declining prices. 

This podcast was recorded as part of the „Let‘s talk rare“ podcast. In this discussion Dr. Stefan Walzer discusses with Owen Bryant, Georgie Rack and Fisentzos Stylianou, all working at Partners 4 Access, the specifics of orphan drugs in the AMNOG context. (https://partners4access.com/insights/podcasts/)

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #germany